Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 1/20 | 0.54 |
| ▸ | CKS1B | P61024 | 2/20 | 0.50 |
| ▸ | SKP1 | P63208 | 2/20 | 0.50 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.50 |
| ▸ | SUV39H2 | Q9H5I1 | 3/20 | 0.47 |
| ▸ | RET | P07949 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | OGA | O60502 | 1/20 | 0.43 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.43 |
| ▸ | BACE1 | P56817 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15599449 | 0.85 | MAP4K4 (0.54) | MAP4K4CKS1BSKP1SKP2SUV39H2 | |
| SCHEMBL31652025 | 0.85 | MAP4K4 (0.54) | MAP4K4CKS1BSKP1SKP2SUV39H2 | |
| SCHEMBL2068165 | 0.85 | MAP4K4 (0.59) | MAP4K4CKS1BSKP1SKP2SUV39H2 | |
| SCHEMBL17310233 | 0.85 | MAP4K4 (0.54) | MAP4K4CKS1BSKP1SKP2SUV39H2 | |
| SCHEMBL22118550 | 0.85 | MAP4K4 (0.56) | MAP4K4CKS1BSKP1SKP2SUV39H2 | |
| SCHEMBL29435004 | 0.85 | MAP4K4 (0.56) | MAP4K4CKS1BSKP1SKP2SUV39H2 | |
| SCHEMBL16333318 | 0.84 | MAP4K4 (0.53) | MAP4K4CKS1BSKP1SKP2SUV39H2 | |
| SCHEMBL15173541 | 0.84 | MAP4K4 (0.64) | MAP4K4CKS1BSKP1SKP2SUV39H2 | |
| SCHEMBL27027530 | 0.84 | MAP4K4 (0.55) | MAP4K4CKS1BSKP1SKP2SUV39H2 | |
| SCHEMBL17375383 | 0.83 | MAP4K4 (0.54) | MAP4K4CKS1BSKP1SKP2SUV39H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250109119-A1 | AMPK AGONISTS AND METHODS OF USE THEREOF | EVVIA THERAPEUTICS INC (US) | 2025-04-03 | — | — | US | disclosed |
| EP-4469436-A1 | AMPK AGONISTS AND METHODS OF USE THEREOF | Evvia Therapeutics, Inc. (US) | 2024-12-04 | — | — | EP | disclosed |
| WO-2023147312-A1 | AMPK AGONISTS AND METHODS OF USE THEREOF | EVVIA THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023147312-A1 | AMPK AGONISTS AND METHODS OF USE THEREOF | EVVIA THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2009001127-A1 | CYANOCYCLOPROPYLCARBOXAMIDES AS CATHEPSIN INHIBITORS | ASTRAZENECA AB (SE) | 2008-12-31 | — | — | WO | disclosed |
| WO-2009001127-A1 | CYANOCYCLOPROPYLCARBOXAMIDES AS CATHEPSIN INHIBITORS | ASTRAZENECA AB (SE) | 2008-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250109119-A1 | AMPK AGONISTS AND METHODS OF USE THEREOF | PRKAG3, PRKAG1, PRKAG2 | MAP4K4 174/4885CKS1B 1244/4885SKP1 4072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.